Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
|Articles|May 31, 2023
- May 2023
- Volume 89
- Issue 5
Last Minute: Pharmacy Pet Peeves
What's bothering the pharmacist?
Advertisement
Coming into the store to drop a prescription off 5 minutes before we close and saying they will wait.
Articles in this issue
over 3 years ago
Generic Product News: May 2023over 3 years ago
Rx Product News: May 2023over 3 years ago
Krazati From Mirati Therapeuticsover 3 years ago
Lowering Cholesterol Case Studiesover 3 years ago
Interactive Case Studies: May 2023over 3 years ago
Safety, Savings Start With Medication Historyover 3 years ago
Does Intermittent Fasting Work?over 3 years ago
Misconnection of Devices to IV Tubing Can Be Fatalover 3 years ago
OTC Product News: May 2023Advertisement
Related to this article
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Pharmacists make a difference in patients’ lives through MTM services.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
5